Evolution Mining share price closes higher as traders eye March dividend date

February 26, 2026
Evolution Mining share price closes higher as traders eye March dividend date

Sydney, February 26, 2026, 18:15 (AEDT) — The market has closed.

  • Evolution Mining ended the day 1.1% higher, settling at A$16.40.
  • Next up for the miner: the ex-dividend date lands on March 3.
  • The Australian dollar edged higher, while the ASX 200 notched a record close—both drawing attention heading into the next session.

Evolution Mining Ltd finished Thursday at A$16.40, climbing 1.1% as shares moved closer to highs set earlier this year following a choppy week. Morningstar data shows the gold miner has rallied roughly 29% year-to-date and surged over 160% in the last 12 months.

The speed is important here: the stock’s acting more like a momentum play than its old reputation as a gold tracker. At these levels, sudden shifts in gold or currency get reflected in the shares almost immediately.

Next up for investors: Evolution’s shares hit their ex-dividend date next week. Anyone buying after that won’t get the payout. The “fully franked” tag in Australia tends to attract more interest, since local shareholders pick up tax credits along with the dividend.

Support held firm across the board. The S&P/ASX 200 notched a fresh record, ending up roughly 0.5% as tech and major mining names did the heavy lifting. Gold stocks, though, weighed on the benchmark.

Evolution last delivered a major update on Feb. 11, posting a record statutory net profit of A$767 million for the half-year ended Dec. 31, along with a fully franked interim dividend of 20 Australian cents per share. Chief executive Lawrie Conway pointed to “operating discipline” and the company’s knack for “capture the upside” when metal prices are strong. ASX Announcements

Gold stocks didn’t move in lockstep. Northern Star Resources, one of the bigger names on the ASX, slipped roughly 2.6% according to the latest numbers, showing how trading has been highly selective across the sector.

Currency remains a wild card here. The Australian dollar traded close to $0.713, hitting its highest mark since August 2022. Traders are betting the Reserve Bank of Australia isn’t done with rate hikes yet. Next week’s calendar brings manufacturing PMI and GDP numbers, per Trading Economics.

For Evolution, focus this week is split: does the bid stay firm into the dividend cutoff, and does bullion keep playing along? Traders will be watching the stock, too, especially if the ASX’s hot streak loses steam.

There’s a hitch. When the Australian dollar strengthens, miners earning in U.S. dollars can see their local revenue squeezed. Even with gold steady, rising input costs can slice margins. And for firms juggling several sites, project execution risk never really goes away.

The company is pointing to FY26 output at 710,000 to 780,000 ounces for gold, copper at 70,000 to 80,000 tonnes, and an all-in sustaining cost—AISC—between A$1,640 and A$1,760 per ounce. That AISC figure reflects what it actually costs to keep operations ticking. Investors tend to watch for any move in those numbers, since that’s what usually pushes the stock one way or the other.

March 3 stands out as the next marker—Evolution stock goes ex-dividend for the interim payout on that date.

Technology News Today

  • UT Austin researchers develop compact CRISPR nuclease for in-body genome editing
    April 13, 2026, 3:55 PM EDT. UT Austin researchers, funded by the NIH and working with Metagenomi Therapeutics, have identified and engineered a compact CRISPR nuclease, Al3Cas12f, that fits into viral delivery systems. The team began from a naturally occurring Cas12f enzyme, 400-700 amino acids long, which could navigate the payload limits of AAV vectors used to deliver gene-editing instructions. Their engineered variant shows improved performance in human cells and outperforms two other Cas12f enzymes previously tested in mice. The work, described in Nature Structural & Molecular Biology, used cryo-electron microscopy and machine learning to reveal mechanistic features that explain efficiency differences, guiding rational design of even better, compact nucleases for potential therapeutic development.